Epirium Bio, Inc., a clinical‑stage biopharmaceutical company focused on neuromuscular and fibrotic diseases, announced positive Phase 1 results for its lead candidate MF‑300, which were presented as a late‑breaker at the Gerontological Society of America Annual Scientific Meeting. The oral small‑molecule therapy inhibits the enzyme 15‑hydroxyprostaglandin dehydrogenase (15‑PGDH) and is intended to treat sarcopenia, age‑related loss of muscle strength and quality for which there are currently no approved therapies.
According to the company, the randomized, double‑blind single‑ and multiple‑ascending‑dose trial in healthy adult volunteers demonstrated that MF‑300 was generally well tolerated, with no serious adverse events or discontinuations reported. Pharmacokinetic analyses showed dose‑related increases in exposure consistent with once‑daily oral dosing. Pharmacodynamic read‑outs revealed dose‑dependent target engagement—specifically increases in prostaglandin E2 (PGE2) and reductions in its metabolite levels—whereas placebo showed no meaningful change. These early biomarker shifts align with preclinical data linking PGE2 elevation to improved muscle force in aged models.
While these results mark a major milestone for Epirium’s pipeline, they are entirely from healthy‑volunteer cohorts; the company emphasises that efficacy in sarcopenia patients remains to be established. Epirium plans to initiate a Phase 2 safety and efficacy trial in mid‑2026 pending the finalisation of Phase 1 data and dose‑selection decisions.
